Market Overview

MLV & Co. Starts Coverage Of DexCom With Buy, $11 PT

In a note out today, MLV & Co. initiated coverage of biotech firm DexCom (Nasdaq: DXCM) with a buy rating and an $11 price target, implying significant upside from where the shares currently trade.

"DexCom, Inc. has proven continuous glucose monitoring technology and strong market share in the large and growing diabetes care market. We think that the Company's lead product, the SEVEN PLUS continuous glucose monitor, is the best device in its class on the market today," MLV said in the note.

Posted-In: Analyst Color News Price Target Initiation FDA Intraday Update Markets Analyst Ratings

 

Most Popular

Related Articles (DXCM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters